BioMarin Pharmaceutical Inc. 2025-2026 Proxy Voting Records

Description as filed by funds: Election of Directors: Alexander Hardy

BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Alexander Hardy”): 163,115,633 for, 1,028,506 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 99.3% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 122 asset managers below reported 80,266,665 for, 4,676 against, 30,100 abstained, 187 not voted.

Showing the 25 largest of 122 asset managers. See all 122 in the interactive database.

Description as filed by funds: Election of Directors: Athena Countouriotis

BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Athena Countouriotis”): 162,326,065 for, 1,823,399 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 122 asset managers below reported 80,266,663 for, 4,678 against, 30,100 abstained, 187 not voted.

Showing the 25 largest of 122 asset managers. See all 122 in the interactive database.

Description as filed by funds: Election of Directors: Barbara W. Bodem

BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Barbara W. Bodem”): 162,832,241 for, 796,989 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 122 asset managers below reported 80,266,664 for, 4,674 against, 30,101 abstained, 187 not voted.

Showing the 25 largest of 122 asset managers. See all 122 in the interactive database.

Description as filed by funds: Election of Directors: Elizabeth M. Anderson

BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Elizabeth M. Anderson”): 152,826,855 for, 11,325,400 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 122 asset managers below reported 77,616,956 for, 2,654,384 against, 30,100 abstained, 187 not voted.

Showing the 25 largest of 122 asset managers. See all 122 in the interactive database.

Description as filed by funds: Election of Directors: Ian T. Clark

BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Ian T. Clark”): 144,380,101 for, 19,160,530 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 88% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 122 asset managers below reported 78,006,912 for, 2,264,427 against, 30,101 abstained, 187 not voted.

Showing the 25 largest of 122 asset managers. See all 122 in the interactive database.

Description as filed by funds: Election of Directors: Mark J. Enyedy

BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Mark J. Enyedy”): 161,113,325 for, 3,032,040 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 122 asset managers below reported 79,509,050 for, 762,290 against, 30,100 abstained, 187 not voted.

Showing the 25 largest of 122 asset managers. See all 122 in the interactive database.

Description as filed by funds: Election of Directors: Maykin Ho

BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Maykin Ho”): 160,849,437 for, 3,300,117 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 122 asset managers below reported 79,877,924 for, 393,416 against, 30,100 abstained, 187 not voted.

Showing the 25 largest of 122 asset managers. See all 122 in the interactive database.

Description as filed by funds: Election of Directors: Robert J. Hombach

BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Robert J. Hombach”): 160,262,501 for, 3,342,524 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 122 asset managers below reported 79,877,924 for, 393,414 against, 30,101 abstained, 187 not voted.

Showing the 25 largest of 122 asset managers. See all 122 in the interactive database.

Description as filed by funds: Election of Directors: Timothy P. Walbert

BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Timothy P. Walbert”): 158,544,683 for, 5,554,116 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 122 asset managers below reported 78,406,401 for, 1,864,938 against, 30,100 abstained, 187 not voted.

Showing the 25 largest of 122 asset managers. See all 122 in the interactive database.

Description as filed by funds: Election of Directors: Willard Dere

BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Willard Dere”): 161,112,606 for, 2,973,541 against, per its Form 8-K filed June 4, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors Based on the votes set forth above, BioMarin's stockholders elected each of the ten nominees set forth above to serve as a director of BioMarin until the next annual meeting of stockholders and until his or her successor is duly elected and qualified, or, if sooner…”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 122 asset managers below reported 79,877,925 for, 393,415 against, 30,100 abstained, 187 not voted.

Showing the 25 largest of 122 asset managers. See all 122 in the interactive database.

Description as filed by funds: To approve an amendment to the Company's 2017 Equity Incentive Plan, as amended.

BioMarin Pharmaceutical Inc.’s own tally for this item (“4. Approval of an Amendment to the 2017 Equity Incentive Plan The approval of the Plan Amendment received the following votes”): 158,561,867 for, 5,480,380 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Based on the votes set forth above, BioMarin's stockholders approved the Plan Amendment.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of BioMarin Pharmaceutical Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Amend Omnibus Stock Plan” (5 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).

The 131 asset managers below reported 79,982,574 for, 184,700 against, 30,100 abstained, 2,907 not voted.

Showing the 25 largest of 131 asset managers. See all 131 in the interactive database.

Description as filed by funds: To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as disclosed in the Proxy Statement.

BioMarin Pharmaceutical Inc.’s own tally for this item (“3. Advisory Vote on the Compensation of Named Executive Officers The advisory (non-binding) vote to approve the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement, received the follo”): 142,742,800 for, 21,287,767 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Based on the votes set forth above, BioMarin's stockholders approved, on an advisory basis, the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement.”
Support: 87% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports, all 121 managers: 75,140,557 for, 5,120,706 against, 34,773 abstained, 187 not voted. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports, all 413 managers: 91,007,761 for, 14,560,792 against, 14,774 abstained, 2,600 not voted, 52 unknown. Showing the 25 largest; see all in the interactive database.

Description as filed by funds: To ratify the selection of KPMG LLP as the independent registered public accounting firm for the Company for the fiscal year ending December 31, 2026.

BioMarin Pharmaceutical Inc.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm The ratification of the selection of KPMG LLP as BioMarin's independent registered public accounting firm for the fiscal year ending Decem”): 170,867,335 for, 4,850,526 against — passed, per its Form 8-K filed June 4, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Based on the votes set forth above, BioMarin's stockholders ratified the selection of KPMG LLP as BioMarin's independent registered public accounting firm to serve for the year ending December 31, 2026.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of BioMarin Pharmaceutical Inc.’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Ratify Appointment of Independent Auditors” (2 managers, Fund and manager reports combined; may count the same shares twice; no share total shown).

The 121 asset managers below reported 80,247,926 for, 19,014 against, 30,100 abstained, 187 not voted.

Showing the 25 largest of 121 asset managers. See all 121 in the interactive database.